Yet, in Re Bilski, the U.S. Supreme Court has now ruled that the current standard for evaluating patents is outdated. That could be a boon for California's bio tech industry, which has seen several potentially profitable gene therapies rejected for failing to meet current patent standard. Hadjis, along with other patent experts says lawyers, Congress, inventors and companies---even those inventing new genes--- have a new opportunity. Adds Hadjis, "The Bilski decision, this opens the door to broader patentability."
Broader patentability could mean bigger profits. According to a 2009 PricewaterhouseCoopers evaluation, California's Bio Medicine industry generates about 80 billion dollars per year.